Hepatitis B and C in Switzerland - Healthcare provider initiated testing for chronic hepatitis B and C infection

Swiss Medical Weekly

Volumn 143, Issue , 2013, Pages

  Fretz, Rainer ^a   Negro, Francesco ^b   Bruggmann, Philip ^b   Lavanchy, Daniel ^b   Gottardi, Andrea De ^b   Pache, Isabelle ^b   Spicher, Virginie Masserey ^a,b   Cerny, Andreas ^b,c  

^a FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^b Swiss Experts in Viral Hepatitis (SEVHep)   (Switzerland)

^c Clinica Luganese   (Switzerland)

Author keywords

Chronic hepatitis infection; HBV; HCV; Risk groups; Screening; Testing

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

BLOOD TRANSFUSION; CHRONIC DISEASE; DIAGNOSTIC TEST; DISEASE TRANSMISSION; EUROPE; FOLLOW UP; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; PATIENT REFERRAL; REVIEW; SCREENING; SEXUAL BEHAVIOR; SWITZERLAND; VERTICAL TRANSMISSION; MASS SCREENING; METHODOLOGY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; RISK ASSESSMENT; SECONDARY PREVENTION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; PROCEDURES;

HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RISK ASSESSMENT; SECONDARY PREVENTION; SWITZERLAND;

EID: 84878398161     PISSN: 14247860     EISSN: 14243997     Source Type: Journal    
DOI: 10.4414/smw.2013.13793     Document Type: Review

References (59)

1. Heymann DL, editor. Control of communicable diseases manual. 19th ed. American Public Health Association; 2008. Viral hepatitis B; p.284-93.
2. Heymann DL, editor. Control of communicable diseases manual. 19th ed. American Public Health Association; 2008. Viral hepatitis C; p.293-95.
3. Colvin HM, Mitchell AE, editors; Committee on the prevention and control of viral hepatitis infections; Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010. Available from: http://www.nap.edu/catalog/12793.html.
4. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol. 2008;22(6):991-1008.
5. Gonzalez SA, Keeffe EB. Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy. Front Biosci. 2011;16:225-50.
6. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48(2):353-67.
7. World Health Organization. Prevention & Control of Viral Hepatitis: Framework for Global Action. World Health Organization 2012. Available from: http://www.who.int/csr/disease/hepatitis/GHP-framework.pdf.
8. Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA et al. Screening and early treatment of migrants for chronic hepatitis b virus infection is cost-effective. Gastroenterology. 2010;(2):522-30.
9. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC; 2010. Available from: http://www.ecdc.europa.eu/en/ publications/Publications/TER-100914-Hep-B-C%20-EU-neighbourhood.pdf.
10. Robert Koch Institut. Ratgeber für Ärzte: Hepatitis B. Stand vom 01.08.2004 [cited 2011 Oct 29]. Available from: http://www.rki.de/DE/ Content/Infekt/EpidBull/Merkblaetter/Ratgeber-HepatitisB.html?nn=2374512. German.
11. Bundesamt für Gesundheit, Referenzzentren für blutübertragbare Infektionen im Gesundheitsbereich. Prävention blutübertragbarer Krankheiten auf Patienten: Empfehlungen für Personal im Gesundheitswesen mit Hepatitis B-, Hepatitis C- oder HIV-Infektion. Richtlinien und Empfehlungen. Bern: Bundesamt für Gesundheit, 2011. German.
12. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107. (Pubitemid 38365759)
13. Heininger U, Vaudaux B, Nidecker M, Pfister RE, Posfay-Barbe KM, Bachofner M et al. Evaluation of the compliance with recommended procedures in newborns exposed to HBsAg-positive mothers: a multicenter collaborative study. Pediatr Infect Dis J. 2010;29(3):248-50.
14. Ambühl PM, Binswanger U, Renner EL. Epidemiologie der chronischen Hepatitis B und C bei Dialysepatienten in der Schweiz. Schweiz Med Wochenschr. 2000;130:341-8. German. (Pubitemid 30154837)
15. Steffen T, Blättler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health. 2001;11(4):425-30. (Pubitemid 33126485)
16. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83.
17. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486-500.
18. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology. 2009.
19. Robert Koch Institut. Ratgeber für Ärzte: Hepatitis C. Stand vom 01.04.2004 [cited 2011 Oct 29]. Available from: http://www.rki.de/DE/ Content/Infekt/EpidBull/Merkblaetter/Ratgeber-HepatitisC.html?nn=2374512.German.
20. Ciesek S, Friesland M, Steinmann J, Becker B, Wedemeyer H, Manns MP et al. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. J Infect Dis. 2010;201(12):1859-66.
21. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52(4):1497-505.
22. Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A et al. Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clin Infect Dis. 2012 Sep 12. [Epub ahead of print].
23. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30-60.
24. Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol. 2002;14(1):25-34. (Pubitemid 34112158)
25. Dubois-Arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S et al. Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. Euro Surveill. 2008;13(21). pii: 18881.
26. Prasad LR, Masserey Spicher V, Kammerlander R, Zwahlen M. Hepatitis C in a sample of pregnant women in Switzerland: seroprevalence and socio-demographic factors. Swiss Med Wkly. 2007;137(1-2):27-32. (Pubitemid 46191228)
27. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74-81.
28. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107-15.
29. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-8.
30. Thompson A, Patel K, Tillman H, McHutchison JG. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol. 2009;50(1):184-94.
31. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16.
32. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
33. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
34. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med. 2011;3(94):94ra71.
35. Piorkowsky NY. Europe's hepatitis challenge: defusing the "viral time bomb". J Hepatol. 2009;51(6):1068-73.
36. World Health Organization. State of the art of new vaccine research and development. 2006. Geneva; Switzerland. Available from: http://whqlibdoc.who. int/hq/2006/WHO-IVB-06.01-eng.pdf.
37. British Association for the Study of the Liver, British Society of Gastroenterology (Liver Section). A time to act: improving liver health and outcomes in liver disease. The national plan for liver services U.K 2009. Available from: http://www.bsg.org.uk/attachments/1004- National%20Liver%20Plan%202009.pdf.
38. Health Protection Agency. Hepatitis C in the UK; 2011. London, July 2011. Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1309969906418.
39. Health Protection Agency. Hepatitis C in the UK; 2007. London, December 2007. Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/ 1204100441645.
40. Bundesamt für Gesundheit. Nationales Programm: HIV und andere sexuell übertragbare Infektionen (NPHS), 2011-2017. Dezember 2010. Available from: http://www.bag.admin.ch/hiv-aids/05464/05465/index.html?lang=de. German.
41. Andermann A. Screening for persons with underlying chronic disease. In: VHPB (Viral Hepatitis Prevention Board) meeting on identification and management of persons with chronic viral hepatitis in Europe; 2010 March 18-19; Budapest, Hungary: p. 2-5.
42. European Observatory on Health Systems and Policies. Policy brief: Screening in Europe. Geneva: WHO; 2006. Available from: http://www.euro.who.int/ -data/assets/pdf-file/0007/108961/E88698.pdf.
43. The Writing Committee on behalf of the Consensus Panel. Expert Consensus Conference: The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. Dig Liver Dis. 2006;38(7):445-51.
44. Goldberg D, Roudot-Thoraval F. In: VHPB (Viral Hepatitis Prevention Board) meeting on identification and management of persons with chronic viral hepatitis in Europe; 2010 March 18-19; Budapest, Hungary: p.1.
45. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health. 2009;19(3):245-53.
46. Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract. 2006;23(4):393-406.
47. Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006;10(32):iii-iv, ix-xii, 1-93.
48. Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for Hepatitis C in injecting drug users: a cost utility analysis. J Public Health. 2004;26(1):61-71. (Pubitemid 38788605)
49. Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008;(11):797-808.
50. Bundesamt für Gesundheit, Eidgenössische Kommission für Impffragen, Arbeitsgruppe Prävention der Mutter-Kind-Übertragung von Hepatitis B. Empfehlungen zur Prävention der Mutter-Kind-Übertragung von Hepatitis-B. Ergänzung zu den Richtlinien und Empfehlungen Nr. 2 (ehemals Supplementum II). Bern: Bundesamt für Gesundheit, 2007. German.
51. Niederhauser C. 11 Jahre nationales Referenzzentrum für Infektionen durch Blut und Blutprodukte. Bull BAG. 2010;10:336-44.
52. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263-70.
53. Murphy EL. The increasing burden of mortality from viral hepatitis in the United States. Ann Intern Med. 2012;157(2):149-50.
54. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR 2012;61(No.RR-4). Available from: http://www.cdc.gov/mmwr/pdf/ rr/rr6104.pdf.
55. European Liver Patients Association, European Association for the study of the Liver. Recommendations for the promotion of case-finding for viral hepatitis B and C, including targeted screening measures for risk groups, February 2009. Available from: http://www.elpa-info.org/tl-files/elpa-downloads/ recommendations-consolidated-version-final.pdf.
56. Ministère de la santé et des sports. Direction générale de la santé. Plan national de lutte contre les Hépatites B et C, 2009-2012. 2010, Paris. Available from: http://www.sante.gouv.fr/IMG/pdf/Plan-national-Hepatites.pdf. French.
57. Health Service Executive. HSE National Social Inclusion. National Hepatitis C Strategy 2011-2014. 2012, Dublin. Available from: http://www.hse.ie/eng/services/Publications/HealthProtection/HepCstrategy.pdf.
58. Bundesamt für Gesundheit. Hepatitis C in der Schweiz: Für eine individuelle Information und Beratung. Bull BAG. 2001;46:877-81. German.
59. Bundesamt für Gesundheit, Schweizerische Kommission für Impffragen, Schweizerische Expertengruppe für virale Hepatitis. Empfehlungen zur Hepatitis-B-Impfung. Richtlinien und Empfehlungen (ehemals Supplementum II). Bern: Bundesamt für Gesundheit, 1997. German.